Research
Hormonal
Abdominal (visceral) obesity is the primary initiator of metabolic syndrome, driving insulin resistance and multi-organ metabolic derangements through elevated free fatty acids, reduced adiponectin, and leptin resistance.
Focus on reducing visceral fat through lifestyle changes rather than just total weight loss. Regular physical activity and dietary adherence (e.g., Mediterranean diet) are key interventions to offset insulin resistance and reduce the risk of metabolic syndrome, regardless of total BMI.
StrongSupportsHIGH confidence
The NCEP panel identifies the root causes of metabolic syndrome as overweight/obesity, physical inactivity, and genetic factors... Fundamentally, the metabolic syndrome reflects disordered energy homeostasis... Most studies support the view that the metabolic syndrome that now confronts U.S. physicians in epidemic proportions is largely initiated by abdominal obesity.
Why this rating
Based on a comprehensive review of clinical definitions, epidemiological data, and mechanistic studies.
Source
Obesity-Initiated Metabolic Syndrome and the Kidney
Susan P. Bagby · Journal of the American Society of Nephrology · 2004
DOI 10.1097/01.asn.0000141965.28037.ee
narrative_reviewCited 258×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Insulin resistance is the essential common denominator of metabolic syndrome, driven by intracellular lipid accumulation (FFA, diacylglycerol) which interferes with insulin signaling pathways (IRS-1 phosphorylation).Strong
- Intrauterine growth restriction (IUGR) and subsequent 'catch-up' growth program the body for increased risk of metabolic syndrome, hypertension, and diabetes in adulthood.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →